Transgene SA, France

Transgene (www.transgene.fr) is a biotechnology company focused on discovering and developing virus-based immunotherapies against cancers. The Company is located in Strasbourg, France.
The Company’s lead clinical-stage programs are: TG4010 for non-small cell lung cancer, Pexa-Vec for liver cancer, TG4001 for HPV-positive head and neck cancers and TG6002 for gastro-intestinal cancers. The Company carries on two major programs: technological program Invir.IO™, and personalized vaccine program myvac™.
Invir.IO™ is dedicated to the design of the next generation of oncolytic viruses. The platform is based on a proprietary Vaccinia based technology that allows Transgene to generate multifunctional immunotherapies aimed at modulating the tumor micro-environment.
Transgene has already demonstrated that its oncolytic viruses derived from its Invir.IO™ platform attack tumors on several fronts, can induce an immunogenic cancer cell death and express several “anti-cancer weapons” in the tumor, such as cytokines, chemokines, enzymes, monoclonal antibodies or minibodies.
myvac™ is an individualized MVA-based immunotherapy platform designed to integrate neoantigens. Two clinical projects are in preparation, and the Company currently improves its manufacturing processes in order to meet delays and costs of such individualized approaches.

Role in the project: